Tipek（Aquaculture）

What is Tipek (Aquaculture)?

Tipek (Aquaculture) is a functional bioactive peptide product used as a fish feed additive. Its core active ingredient is recombinant Epidermal Growth Factor (EGF), gene-engineered and produced via precision yeast fermentation — consistent biological activity, no antibiotic components, no animal-derived inputs, and no drug residue concerns.

The intestinal tract of fish is both the primary site of nutrient absorption and a critical component of mucosal immune defense. EGFR is a 170 kDa transmembrane receptor tyrosine kinase that is highly conserved in vertebrates including fish, where it regulates epithelial cell proliferation, differentiation, and intestinal development. In intensive aquaculture conditions, the intestinal epithelium faces constant challenge from high stocking density stress, feed quality variation, and pathogen colonization — disrupting the mucosal barrier and reducing feed conversion efficiency. Tipek delivers recombinant EGF to activate EGFR-mediated intestinal repair and development, restoring absorptive function and supporting consistent growth performance.

How Does Tipek (Aquaculture) Work?

Recombinant EGF binds to EGFR expressed on fish intestinal epithelial cells, triggering autophosphorylation and activation of downstream signaling pathways — including Ras/MAPK, PI3K/AKT, and STATS — that regulate intestinal cell proliferation, differentiation, and barrier function. This conserved signaling mechanism drives four measurable outcomes:

Promote Intestinal Development

Stimulates intestinal epithelial cell proliferation and differentiation. Increases mucosal fold height and absorptive surface area. Promotes intestinal tissue maturation — particularly important in early life stages when the intestinal tract is still developing and vulnerable to environmental stress.

Repair Mucosal Injury

Rapidly repairs intestinal epithelial damage caused by pathogens, feed toxins, or environmental stress. Restores tight junction integrity to prevent increased intestinal permeability and secondary pathogen invasion. EGF-mediated mucosal restitution is particularly valuable in intensive aquaculture where continuous low-grade intestinal stress is common.

Strengthen Mucosal Immune Barrier

Enhances the structural and immune integrity of the intestinal mucosa. Reduces pathogenic microbial colonization and invasion. Supports the mucosal immune response, improving disease resistance and reducing mortality risk under high-density rearing conditions.

Improve Feed Conversion Efficiency

Promotes digestive enzyme secretion and nutrient transporter expression. Improves the digestion and absorption efficiency of energy, protein, and key minerals — the direct mechanism behind improved specific growth rate (SGR), lower FCR, and better feed cost efficiency.

The EGFR signaling pathway is among the most evolutionarily conserved mechanisms in vertebrate biology. EGF receptor expression has been confirmed in the intestinal tract of multiple commercially important fish species, including salmon, tilapia, carp, and sea bass.

What are the Benefits of Tipek（Aquaculture)?

Gut Health:

Disease Resilience:

Production Economics:

• Improves specific growth rate (SGR)
• Reduces feed conversion ratio (FCR)
• Increases final harvest weight
  
  
  
  

• Increases intestinal mucosal fold height and absorptive surface area
• Reduces intestinal inflammation and mucosal damage
• Improves intestinal barrier integrity and tight junction expression
  
  

• Enhances mucosal immune barrier function
• Reduces mortality under high-density rearing stress
• Supports recovery of gut function after disease challenge or antibiotic treatment
  

• Lower feed cost per kg of fish produced
• Reduced antibiotic dependency
• Compatible with antibiotic-free certification programs
  
  
  

Trial Design: Shrimp of uniform size and good health status were assigned to a Control Group and a Treatment Group (TIPEK inclusion rate: 1,000 g/t feed).

Location: Zhangzhou, Fujian, China.

Duration: 10 weeks (2025).

Largemouth bass of similar body weight and age were randomly assigned to two groups: a Control Group and a Trial Group. Each group was stocked in a 0.33-hectare pond with 11,000 fish. The trial Group received TIPEK at an inclusion rate of 500 g/t of feed.

Trial Period : May 10, 2024 – June 9, 2024

Trial Location :A commercial largemouth bass farm in Chengdu,Sichuan Province, China.

Trial Conclusions:

• The treatment group showed a 17.8 g increase in final mean body weight compared to the control group, representing an 11.2% improvement.
• The treatment group outperformed the control group in both body length and intestinal length, with increases of 1.7 cm and 3.2 cm, respectively, corresponding to improvements of 8.3% and 18.5%, respectively.
• The treatment group exhibited a 3.6 kg increase in average daily feed intake (ADFI) compared to the control group, representing a 16.1% improvement.
• The treatment group showed a 0.08 reduction in feed conversion ratio (FCR) compared to the control group.

TIPEK FAQ